KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.

View in: PubMed

subject areas

Adolescent
Adult
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Chemotherapy, Adjuvant
Child
Clinical Trials, Phase III as Topic
Cross-Over Studies
Dermatologic Surgical Procedures
Disease-Free Survival
Female
Humans
Male
Melanoma
Multicenter Studies as Topic
Neoplasm Recurrence, Local
Neoplasm Staging
Placebos
Programmed Cell Death 1 Receptor
Randomized Controlled Trials as Topic
Skin Neoplasms
Young Adult